Karolinska Development AB (publ) (STO: KDEV)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 281.17M |
| Revenue (ttm) | 1.88M |
| Net Income (ttm) | -28.53M |
| Shares Out | 269.83M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 359,812 |
| Open | 1.070 |
| Previous Close | 1.084 |
| Day's Range | 1.024 - 1.096 |
| 52-Week Range | 0.950 - 1.948 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2024 |
About Karolinska Development AB
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio com... [Read more]
Financial Performance
Financial StatementsNews
Karolinska Development’s portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO
STOCKHOLM, Sweden, 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will a...